Genomic Health has joined forces with Belgium-based molecular diagnostics company Biocartis to develop an in vitro diagnostics (IVD) version of Genomic Health’s Oncotype Dx Breast Recurrence Score test. The Oncotype Dx Breast Recurrence Score examines the activity of 21 genes in a patient’s breast tumor tissue to predict chemotherapy benefit and help healthcare providers to tailor treatment based on a patient’s individual biology. The current version of the test, included in all major cancer guidelines worldwide, is considered standard of care for early-stage breast cancer. This strategic collaboration will provide Genomic Health with exclusive worldwide rights to develop and commercialize the Oncotype Dx Breast Recurrence Score on Biocartis’ Idylla platform, a fully automated sample-to-answer, real-time polymerase chain reaction-based system. Development of the Oncotype Dx IVD test is expected to begin in late 2017, with the aim of providing initial access to patients in Europe, beginning with France and Germany, in 2019.